Education
About Us
Working with TipRanks
Follow Us
Catalyst Pharmaceutical Partners (CPRX)
NASDAQ:CPRX
CPRX Stock Chart & Stats
$24.45
-$0.35(-1.79%)
At close: 4:00 PM EST
$24.45
-$0.35(-1.79%)
Day’s Range― - ―
52-Week Range$19.05 - $26.58
Previous CloseN/A
Volume328.11K
Average Volume (3M)1.11M
Market Cap
$3.00B
Enterprise Value$2.32B
Total Cash (Recent Filing)$689.89M
Total Debt (Recent Filing)$2.89M
Price to Earnings (P/E)14.3
Beta0.68
Next Earnings
Mar 18, 2026EPS Estimate
0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.42
Shares Outstanding122,912,384
10 Day Avg. Volume1,165,971
30 Day Avg. Volume1,113,531
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)3.40
Price to Sales (P/S)5.03
P/FCF Ratio10.33
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue4.01
Enterprise Value/Gross Profit4.80
Enterprise Value/Ebitda7.62
Forecast
1Y Price Target
$35.00Price Target Upside43.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.75
Revenue Forecast (FY)$615.30M
Bulls Say, Bears Say
Bulls Say
Commercial LaunchHigh payer approval rates combined with a streamlined fulfillment process accelerate patient access to Agamree and support sustained revenue expansion.
Legal And Competitor Manufacturing SetbacksFDA inspection issues at a competitor's manufacturing facility plus stalled settlement talks increase the probability that the brand retains effective market exclusivity, protecting Firdapse market share.
Oncology Market ExpansionGuideline updates and wider adoption of targeted testing in oncology centers expand identification of cancer-associated LEMS patients, creating a sizeable growth runway for Firdapse.
Bears Say
Capital ConstraintsLimited willingness to use debt for financing restricts ability to fund higher-risk clinical-stage programs, potentially slowing pipeline advancement.
Generic CompetitionEntry of multiple generics is expected to materially erode Fycompa revenue, posing downside pressure on future performance.
Patent Litigation RiskInherent unpredictability of patent litigation outcomes creates material uncertainty around future market access for key products.
Catalyst Pharma News
CPRX FAQ
What was Catalyst Pharmaceutical Partners’s price range in the past 12 months?
Catalyst Pharmaceutical Partners lowest stock price was $19.05 and its highest was $26.58 in the past 12 months.
What is Catalyst Pharmaceutical Partners’s market cap?
Catalyst Pharmaceutical Partners’s market cap is $3.00B.
When is Catalyst Pharmaceutical Partners’s upcoming earnings report date?
Catalyst Pharmaceutical Partners’s upcoming earnings report date is Mar 18, 2026 which is in 34 days.
How were Catalyst Pharmaceutical Partners’s earnings last quarter?
Catalyst Pharmaceutical Partners released its earnings results on Nov 05, 2025. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.332 by $0.088.
Is Catalyst Pharmaceutical Partners overvalued?
According to Wall Street analysts Catalyst Pharmaceutical Partners’s price is currently Undervalued.
Does Catalyst Pharmaceutical Partners pay dividends?
Catalyst Pharmaceutical Partners does not currently pay dividends.
What is Catalyst Pharmaceutical Partners’s EPS estimate?
Catalyst Pharmaceutical Partners’s EPS estimate is 0.34.
How many shares outstanding does Catalyst Pharmaceutical Partners have?
Catalyst Pharmaceutical Partners has 122,912,384 shares outstanding.
What happened to Catalyst Pharmaceutical Partners’s price movement after its last earnings report?
Catalyst Pharmaceutical Partners reported an EPS of $0.42 in its last earnings report, beating expectations of $0.332. Following the earnings report the stock price went down -1.824%.
Which hedge fund is a major shareholder of Catalyst Pharmaceutical Partners?
Currently, no hedge funds are holding shares in CPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Catalyst Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.00 (43.15% Upside)
$35.00 (43.15% Upside)
Blogger Sentiment
Bullish
CPRX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $878.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 6.4%
Last 30 Days ▼ 6.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.76%
12-Months-Change
Fundamentals
Return on Equity
27.52%
Trailing 12-Months
Asset Growth
36.22%
Trailing 12-Months
Company Description
Catalyst Pharmaceutical Partners
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
CPRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Catalyst Pharmaceuticals' strong financial performance, driven by significant growth in FIRDAPSE and AGAMREE, as well as the company's solid cash position and raised revenue guidance. However, the decline in FYCOMPA revenue due to generic competition and ongoing patent litigation for FIRDAPSE were noted challenges.View all CPRX earnings summariesCPRX Stock 12 Month Forecast
Average Price Target
$35.00
▲(43.15% Upside)
Technical Analysis
Amicus
―
Travere Therapeutics
―
Ocular Therapeutix
―
ImmunityBio
―
Liquidia Technologies
―
Ownership Overview
6.14% Insiders
17.58% Mutual Funds
0.36% Other Institutional Investors
49.20% Public Companies and Individual Investors